Semaglutide
Semaglutide is a peptide, indexed here under Incretin receptor agonists.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Incretin receptor agonists |
| CAS registry number | 910463-68-2[1] |
| PubChem CID | 56843331[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C187H291N45O59[1] |
| Molecular weight | 4114 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Semaglutide is a long-acting incretin receptor agonist. The clinical literature indexed for it is dominated by large randomised trials with cardiovascular and metabolic endpoints: a 2016 New England Journal of Medicine report on cardiovascular outcomes in patients with type 2 diabetes, a 2021 report on once-weekly administration in adults with overweight or obesity, and a 2023 report on cardiovascular outcomes in obesity without diabetes.
Further retrieved trial reports extend the endpoint set beyond glycaemic control: a 2021 placebo-controlled trial in nonalcoholic steatohepatitis and a 2024 trial of effects on chronic kidney disease in patients with type 2 diabetes. A 2021 head-to-head trial compared once-weekly tirzepatide with once-weekly semaglutide in type 2 diabetes.
[3, 4, 5, 6, 7, 8]Reported mechanism
Agonist at the glucagon-like peptide-1 receptor, the single-receptor mechanism of the incretin receptor agonist class.
[9, 10]Derived: the retrieved citation metadata for this compound does not state the receptor in a title. The receptor mechanism is taken from the cited 2024 GLP-1 receptor review, and this compound is placed in that class by the cited 2024 BMJ network meta-analysis of GLP-1 receptor agonists.
Targets named in the cited records: GLP-1 receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including NDA213051, marketed as OZEMPIC, RYBELSUS). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Semaglutide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- NN9535
- NNC 0113-0217
Where this page sits
Research records
Cited research records for Semaglutide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Side-by-side pages that include Semaglutide
- Cagrilintide and Semaglutide side by side
- Liraglutide and Semaglutide side by side
- Semaglutide and Tirzepatide side by side
Compounds indexed next to it
- Tirzepatide — Incretin receptor agonists
- Liraglutide — Incretin receptor agonists
- Retatrutide — Incretin receptor agonists
- Cagrilintide — Amylin and amylin receptor agonists
- Dulaglutide — Incretin receptor agonists
- GLP-1 — Incretin receptor agonists
- Orforglipron — Incretin receptor agonists
Named targets in the cited records
Class page: Incretin receptor agonists. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Semaglutide?
Semaglutide is a long-acting incretin receptor agonist. The clinical literature indexed for it is dominated by large randomised trials with cardiovascular and metabolic endpoints: a 2016 New England Journal of Medicine report on cardiovascular outcomes in patients with type 2 diabetes, a 2021 report on once-weekly administration in adults with overweight or obesity, and a 2023 report on cardiovascular outcomes in obesity without diabetes.
Which class is Semaglutide indexed under?
Semaglutide is indexed under Incretin receptor agonists. Incretin receptor agonists are synthetic peptides that bind one or more of the incretin and glucagon family receptors, principally the glucagon-like peptide-1 receptor.
What does the FDA application register show for Semaglutide?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including NDA213051, marketed as OZEMPIC, RYBELSUS). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.
Sources
- PubChem Compound Summary for CID 56843331, Semaglutide. PubChem, National Library of Medicine (2026). pubchem:56843331
- Drugs@FDA application register query for this compound, 1 application(s) returned: NDA213051. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:semaglutide
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med (2016). pmid:27633186
- Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med (2021). pmid:33567185
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med (2023). pmid:37952131
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med (2021). pmid:33185364
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med (2024). pmid:38785209
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med (2021). pmid:34170647
- Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther (2024). pmid:39289339
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ (2024). pmid:38286487
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.